Compare GL & ELAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GL | ELAN |
|---|---|---|
| Founded | 1900 | 1954 |
| Country | United States | United States |
| Employees | 3695 | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.9B | 12.7B |
| IPO Year | N/A | 2018 |
| Metric | GL | ELAN |
|---|---|---|
| Price | $154.17 | $24.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 10 |
| Target Price | ★ $167.27 | $27.89 |
| AVG Volume (30 Days) | 440.6K | ★ 6.6M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.71% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.11 |
| Revenue | N/A | ★ $4,715,000,000.00 |
| Revenue This Year | $9.64 | $8.21 |
| Revenue Next Year | $5.61 | $5.31 |
| P/E Ratio | ★ $10.21 | $214.77 |
| Revenue Growth | N/A | ★ 6.22 |
| 52 Week Low | $116.73 | $13.09 |
| 52 Week High | $157.92 | $27.72 |
| Indicator | GL | ELAN |
|---|---|---|
| Relative Strength Index (RSI) | 52.25 | 59.78 |
| Support Level | $150.88 | $23.72 |
| Resistance Level | $155.60 | $25.78 |
| Average True Range (ATR) | 3.31 | 1.12 |
| MACD | -0.30 | 0.33 |
| Stochastic Oscillator | 57.46 | 90.73 |
Globe Life Inc is an insurance holding company. It provides a variety of life and supplemental health insurance products and annuities to a broad base of customers. The company's core operations are organized into three reportable segments: life insurance, supplemental health insurance and investments. Investment activities, conducted by the investment segment, focus on seeking investments with a yield and term appropriate to support the insurance product obligations. These investments generally consist of fixed maturities and, over the long term, the expected yields are considered when setting insurance premium rates and product profitability expectations.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.